Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 16 de 16
Filter
1.
Gene ; 851: 147030, 2023 Jan 30.
Article in English | MEDLINE | ID: mdl-36351549

ABSTRACT

Advanced glycation end products (AGEs) disturb endothelial barrier function and contribute to age-related diseases. As microRNAs (miRNAs) are potential therapeutic agents, targeting AGEs-associated signaling using miRNAs in endothelial cells may be an effective intervention strategy for age-related vascular disorders. This study investigated the effects of AGEs on the endothelial cell senescence and barrier function in human umbilical vein endothelial cells (HUVECs). HUVECs were treated with AGEs and transfected with miRNA-1-3p mimics to induce overexpression of miR-1-3p. Senescence-associated ß-galactosidase (SA-ß-Gal) staining and senescence-related proteins P53, P21, and P16 were detected to evaluate the endothelial cell senescence. The expression levels of myosin light chain kinase (MLCK) signaling and transendothelial electric resistance (TEER) were used to indicate endothelial barrier function. AGEs significantly increased SA-ß-gal staining-positive cells accompanied by the upregulation of P53, P21, and P16 expression. AGEs also damaged endothelial barrier function by decreasing TEER and increasing zonula occludens protein 1, p-MLC/MLC, and MLCK. miRNA-1-3p was significantly reduced in HUVECs treated with AGEs. miR-1-3p overexpression decreased MLCK signal and improved AGEs-induced endothelial barrier function impairment. Meanwhile, miR-1-3p overexpression ameliorated oxidative stress and endothelial cell senescence induced by AGEs. AGEs induced endothelial cell senescence and endothelial barrier dysfunction by regulating miR-1-3p/MLCK signaling pathway.


Subject(s)
MicroRNAs , Myosin-Light-Chain Kinase , Humans , Cellular Senescence , Human Umbilical Vein Endothelial Cells/metabolism , MicroRNAs/metabolism , Myosin-Light-Chain Kinase/metabolism , Myosin-Light-Chain Kinase/pharmacology , Signal Transduction , Tumor Suppressor Protein p53/metabolism , Glycation End Products, Advanced/metabolism
2.
EBioMedicine ; 49: 72-81, 2019 Nov.
Article in English | MEDLINE | ID: mdl-31680003

ABSTRACT

BACKGROUND: No effective approaches to target mutant Kras have yet been developed. Immunoprevention using KRAS-specific antigenic peptides to trigger T cells capable of targeting tumor cells relies heavily on lipid metabolism. To facilitate better TCR/peptide/MHC interactions that result in better cancer preventive efficacy, we combined KVax with avasimibe, a specific ACAT1 inhibitor, tested their anti-cancer efficacy in mouse lung cancer models, where Kras mutation was induced before vaccination. METHODS: Control of tumor growth utilizing a multi-peptide Kras vaccine was tested in combination with avasimibe in a syngeneic lung cancer mouse model and a genetically engineered mouse model (GEMM). Activation of immune responses after administration of Kras vaccine and avasimibe was also assessed by flow cytometry, ELISpot and IHC. FINDINGS: We found that Kras vaccine combined with avasimibe significantly decreased the presence of regulatory T cells in the tumor microenvironment and facilitated CD8+ T cell infiltration in tumor sites. Avasimibe also enhanced the efficacy of Kras vaccines target mutant Kras. Whereas the Kras vaccine significantly increased antigen-specific intracellular IFN-γ and granzyme B levels in CD8+ T cells, avasimibe significantly increased the number of tumor-infiltrating CD8+ T cells. Additionally, modulation of cholesterol metabolism was found to specifically impact in T cells, and not in cancer cells. INTERPRETATION: Avasimibe complements the efficacy of a multi-peptide Kras vaccine in controlling lung cancer development and growth. This treatment regimen represents a novel immunoprevention approach to prevent lung cancer.


Subject(s)
Acetates/pharmacology , Cancer Vaccines/immunology , Proto-Oncogene Proteins p21(ras)/immunology , Sulfonic Acids/pharmacology , Vaccines, Subunit/immunology , Acetamides , Amino Acid Sequence , Animals , Cholesterol/metabolism , Disease Progression , Lung Neoplasms/immunology , Lung Neoplasms/pathology , Mice , Proto-Oncogene Proteins p21(ras)/chemistry , Sulfonamides , T-Lymphocytes, Regulatory/immunology
3.
Onco Targets Ther ; 10: 1279-1284, 2017.
Article in English | MEDLINE | ID: mdl-28280362

ABSTRACT

There is debate surrounding which treatment is superior in overall survival (OS) rates in patients with epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC); first-line tyrosine kinase inhibitor (TKI) followed by second-line platinum-based doublet chemotherapy (PCT), or the reverse sequence. Cross treatment of first- and second-line TKI and PCT makes it difficult to deduce which sequence (TKI-PCT or PCT-TKI) is better for OS. Using the keywords "lung cancer" and "EGFR" we identified clinical trials within the PubMed database which were published between January 2006 and November 2016. Basic characteristics and OS with hazard ratio and 95% confidence intervals were searched and analyzed. In total, 457 articles were reviewed and nine clinical trials with 1,876 patients were of sufficient quality for further analysis. Fixed effects models were performed to pool the data in this meta-analysis. All nine studies were open-labeled, multicenter, Phase III randomized controlled clinical trials. The pooled hazard ratio was 0.96 (95% confidence interval: 0.84-1.10) for OS between first-line TKI followed by second-line PCT compared to the reverse sequence. No statistically significant heterogeneity (I2=0, P=0.553) nor publication bias (Egger's P=0.991) was observed among these studies. In conclusion, there was no OS benefit between first-line TKI followed by second-line PCT compared to the reverse sequence in EGFR mutant NSCLC patients. Chemotherapy was still useful and irreplaceable for the treatment of NSCLC, especially for those patients with EGFR unavailable for testing.

4.
Case Rep Oncol ; 7(3): 789-98, 2014 Sep.
Article in English | MEDLINE | ID: mdl-25566054

ABSTRACT

A 62-year-old woman was found to have multiple bilateral pulmonary nodules showing different (18)F-fluorodeoxyglucose (FDG) uptakes on positron-emission tomography/computed tomography (PET/CT). Only the largest nodule in the left lower lobe showed an increased (18)F-FDG uptake on PET/CT. Three nodules were surgically resected from different lobes of the left lung. Two lobes were benign and showed amyloid deposition. The largest nodule in the left lower lobe showed adenocarcinoma and a heavy amyloid deposition. Pulmonary amyloidosis should be added to the differential diagnosis for cases with multiple pulmonary nodules that show different (18)F-FDG uptakes on PET/CT. To the best of our knowledge, this is the second reported case of a lung nodule consisting of adenocarcinoma and amyloid deposition.

5.
Molecules ; 18(1): 1214-26, 2013 Jan 17.
Article in English | MEDLINE | ID: mdl-23344209

ABSTRACT

Intestinal ischemia-reperfusion (I/R) is a critical event in the pathogenesis of multiple organ dysfunction syndromes (MODS). The lungs are some of the most vulnerable organs that are impacted by intestinal I/R. The aim of this study is to investigate whether ginsenoside Rb1 can ameliorate remote lung injury induced by intestinal I/R. Adult male Wistar rats were randomly divided into four groups: (1) a control, sham-operated group (sham group); (2) an intestinal I/R group subjected to 1 h intestinal ischemia and 2 h reperfusion (I/R group); (3) a group treated with 20 mg/kg ginsenoside Rb1 before reperfusion (Rb1-20 group); and (4) a group treated with 40 mg/kg ginsenoside Rb1 before reperfusion (Rb1-40 group). Intestinal and lung histology was observed. The malondialdehyde (MDA) levels in intestinal tissues were measured. Myeloperoxidase (MPO), TNF-α, MDA levels, wet/dry weight ratio and immunohistochemical expression of intracellular adhesion molecule-1 (ICAM-1) in lung tissues were assayed. In addition, a western blot of lung NF-kB was performed. Results indicated that intestinal I/R induced intestinal and lung injury, which was characterized by increase of MDA levels and pathological scores in intestinal tissues and MPO, TNF-α , MDA levels, wet/dry weight ratio and ICAM-1, NF-kB expression in the lung tissues. Ginsenoside Rb1 (20, 40 mg/kg) ameliorated intestinal and lung injury, decreased MPO, TNF-α, MDA levels, wet/dry weight ratio, ICAM-1 and NF-kB expression in lung tissues. In conclusion, ginsenoside Rb1 ameliorated the lung injuries by decreasing the NF-kB activation-induced inflammatory response.


Subject(s)
Anti-Inflammatory Agents/administration & dosage , Antioxidants/administration & dosage , Ginsenosides/administration & dosage , Lung Injury/drug therapy , Reperfusion Injury/drug therapy , Animals , Intercellular Adhesion Molecule-1/metabolism , Intestinal Mucosa/pathology , Intestine, Small/blood supply , Intestine, Small/drug effects , Intestine, Small/pathology , Lung/drug effects , Lung/metabolism , Lung Injury/etiology , Male , Malondialdehyde/metabolism , Mesenteric Arteries/pathology , Mesenteric Vascular Occlusion/complications , Mesenteric Vascular Occlusion/drug therapy , Oxidative Stress , Peroxidase/metabolism , Rats , Rats, Wistar , Reperfusion Injury/complications , Transcription Factor RelA/metabolism , Tumor Necrosis Factor-alpha/metabolism
6.
Exp Lung Res ; 36(4): 201-10, 2010 May.
Article in English | MEDLINE | ID: mdl-20426528

ABSTRACT

Abnormal hypertrophy and hyperplasia of airway smooth muscle cells play an important role in airway remodeling in chronic asthma. The authors' previous studies have indicated that protein kinase C alpha (PKC alpha) is involved in the proliferation of passively sensitized human airway smooth muscle cells (HASMCs). However, the underlying mechanisms remain unknown. Here, the authors examined the possible role of the alpha isoform of PKC in the control of cyclin D1 expression, using HASMCs passively sensitized on human atopic asthmatic serum as a model system. Cultured HASMCs were passively sensitized with serum from atopic asthmatic patients. Cell proliferation was measured by [(3)H]thymidine incorporation and an MTT assay. Cell cycle status was analyzed by flow cytometry. The mRNA and protein expression profiles of cyclin D1 were measured by reverse transcriptase-polymerase chain reaction (RT-PCR) and Western blotting, respectively. Furthermore, the authors assessed the role of cyclin D1 in PKC alpha-induced HASMC proliferation by transfection with a recombinant cyclin D1 antisense construct. The activation of PKC alpha with phorbol myristate acetate (PMA), a PKC activator, up-regulated cyclin D1 expression and increased the proliferation of passively sensitized HASMCs. This effect was significantly decreased by specific inhibition of PKC alpha with Go6976. In addition, the authors showed that transfection with antisense cyclin D1 abolished PMA-induced G1/S progression and HASMC proliferation. These results demonstrate that PKC alpha promotes the proliferation of HASMCs sensitized with atopic asthmatic serum via up-regulation of cyclin D1 expression.


Subject(s)
Asthma/enzymology , Bronchi/enzymology , Cell Proliferation , Cyclin D1/metabolism , Myocytes, Smooth Muscle/physiology , Protein Kinase C-alpha/metabolism , Adult , Asthma/pathology , Bronchi/pathology , Carbazoles , Cells, Cultured , Female , Humans , Isoenzymes , Male , Middle Aged , Serum , Tetradecanoylphorbol Acetate , Up-Regulation , Young Adult
7.
Chin Med J (Engl) ; 121(20): 2070-6, 2008 Oct 20.
Article in English | MEDLINE | ID: mdl-19080278

ABSTRACT

BACKGROUND: Airway smooth muscle (ASM) is suspected to be a determining factor in the structural change of asthma. However, the role of protein kinase C alpha (PKCalpha) and cyclin D1 involved in the dysfunction of ASM leading to asthmatic symptoms is not clear. In this study, the central role of PKCalpha and cyclin D1 in ASM proliferation in asthmatic rats was explored. METHODS: Thirty-six pathogen-free male Brown Norway (BN) rats were randomly divided into 2 groups: control groups (group N1, N2 and N3) and asthmatic groups (group A1, A2, and A3). Groups A1, A2 and A3 were challenged with ovalbumin (OA) for 2 weeks, 4 weeks and 8 weeks respectively. Control animals were exposed to an aerosolized sterile phosphate buffered saline (PBS). The ASM mass and nucleus numbers were studied to estimate the degree of airway remodeling by the hematoxylin-eosin staining method. PKCalpha and cyclin D1 expression in the ASM cells was detected by reverse transcription polymerase chain reaction (RT-PCR) and immunohistochemistry. The relation between PKCalpha and cyclin D1 was assessed by linear regression analysis. PKC agonist phorbol 12-myristate 13-acetate (PMA), PKC inhibitor Ro31-8220 and an antisense oligonucleotide against cyclin D1 (ASOND) were used to treat ASM cells (ASMCs) obtained from the 2 weeks asthmatic rats. The cyclin D1 protein expression level was detected by Western blotting. RESULTS: Compared with the control group, the PKCalpha and cyclin D1 mRNA levels were increased in the asthmatic group. Similar to RT-PCR results, immunohistochemistry analysis for PKCalpha and cyclin D1 expression revealed an increased production in ASMCs after allergen treatment for 2, 4 and 8 weeks compared with the respective control groups. No difference in expression of PKCalpha and cyclin D1 in ASM were found in the 2, 4 or 8 weeks asthmatic rats. There were significant positive correlations between PKCalpha and cyclin D1 expression, both transcriptionally (r = 0.944, P < 0.01) and translationally (r = 0.826, P < 0.01), in ASM. The content of cyclin D1 in asthmatic ASMCs increased after being stimulated by PMA, and decreased when induced by Ro31-8220. ASOND targeting for cyclin D1 lowered the expression of cyclin D1 induced by PMA. CONCLUSIONS: Increased expression of PKCalpha and cyclin D1 in ASM along with smooth muscle structure changes might implicate PKCalpha and cyclin D1 participation in the proliferation of ASM and contribute to the pathogenesis of asthma after repeated allergen exposure in rats. The results suggested that cyclin D1 might be downstream of PKC signal transduction pathway.


Subject(s)
Asthma/pathology , Cyclin D1/physiology , Lung/pathology , Myocytes, Smooth Muscle/pathology , Protein Kinase C-alpha/physiology , Animals , Cell Proliferation , Cyclin D1/genetics , Male , Protein Kinase C-alpha/genetics , RNA, Messenger/analysis , Rats , Rats, Inbred BN
8.
Ai Zheng ; 27(7): 710-5, 2008 Jul.
Article in Chinese | MEDLINE | ID: mdl-18606063

ABSTRACT

BACKGROUND & OBJECTIVE: Recent studies have shown that activation of nuclear factor-kappaB(NF-kappaB) can regulate the invasion and metastasis of cancer cells. The present study was to investigate inhibition of NF-kappaB activity on invasion of human lung cancer cell line A549 and the possible mechanism. METHODS: The recombinant plasmid pcDNA3.1(+)/IkappaBalpha, expressing the alpha isoform (IkappaBalpha) of the NF-kappaB inhibitor, was constructed. A549 cells were cultured in vitro and divided into non-transfection group, pcDNA3.1(+) transfected group and pcDNA3.1(+)/IkappaBalpha transfected group. The expression of IkappaBalpha was detected by reverse transcription-polymerase chain reaction (RT-PCR) and Western blotting. The activity of NF-kappaB was determined by electrophoretic mobility shift assay (EMSA). Invasion of A549 cells was assessed by transwell chamber assay. The expression of MMP-2 and MMP-9 was detected by RT-PCR and gelatin zymography. RESULTS: Plasmid pcDNA3.1(+)/IkappaBalpha was successfully constructed and expressed in A549 cells. The activity of NF-kappaB, the number of invasive cells, the activity of MMP-2 and MMP-9 of A549 cells in pcDNA3.1(+)/IkappaBalpha transfected group were significantly lower than those in non-transfection group and pcDNA3.1(+) transfected group (all P<0.05). CONCLUSION: Transfection of IkappaBalpha can inhibit NF-kappaB activity, thus inhibit cell invasion of A549, which may be through the down-regulation of MMP-2 and MMP-9 expressions.


Subject(s)
I-kappa B Proteins/physiology , Lung Neoplasms/pathology , NF-kappa B/antagonists & inhibitors , Cell Line, Tumor , Humans , I-kappa B Proteins/genetics , Matrix Metalloproteinase 2/analysis , Matrix Metalloproteinase 2/genetics , Matrix Metalloproteinase 9/analysis , Matrix Metalloproteinase 9/genetics , Matrix Metalloproteinase Inhibitors , NF-KappaB Inhibitor alpha , Neoplasm Invasiveness , RNA, Messenger/analysis , Transfection
9.
Yao Xue Xue Bao ; 43(3): 247-52, 2008 Mar.
Article in Chinese | MEDLINE | ID: mdl-18630259

ABSTRACT

This study is to investigate the expression of CyclinD1 in asthmatic rats and construct expression plasmids of sense and antisense CyclinD1 gene and transfect them to asthmatic airway smooth muscle cell to study the effects of CyclinD1 on the proliferation of airway smooth muscle cells in asthmatic rats. CyclinD1 cDNA was obtained by RT-PCR of total RNA extracted from the airway smooth muscle in asthmatic rats. The sequence was inserted into eukaryotic expression vector pcDNA3.1 (+) to recombinate the sense and antisense pcDNA3.1-CyclinD1 eukaryotic expression vector. The two recombinations and vector were then separately transfected into airway smooth muscle cell in asthmatic rats by using liposome. The expression level of CyclinD1 was certificated by Western blotting analysis. The proliferations of ASMCs isolated from asthmatic rats were examined with cell cycle analysis, MTT colorimetric assay and proliferating cell nuclear antigen (PCNA) immunocytochemical staining. Results showed (1) Compared with control group, the content of CyclinD1 was significantly increased; (2) It was comformed by restriction endonucleasa digestion and DNA sequence analysis that the expression plasmid of sense and antisense CyclinD1 were successfully recombinated. There was significant change of CyclinD1 expression between vector and sense CyclinD1 transfected cells, and the expression level of CyclinD1 in ASMC transfected with antisense CyclinD1 was lower than that in vector transfected cells (P <0.01); (3) In the asthmatic groups, compared with the vecter group, the percentage of S + G2M phase, absorbance A value of MTT and the expression rate of PCNA protein in ASMC transfected with pcDNA3. 1-CyclinD1 vector significantly increased. The values decreased remarkably in the pcDNA3,1-as CyclinD1 group. Statistical analysis revealed that there were significant differences in these indicators of cell proliferation in three groups (P <0.01). In the normal groups, statistical analysis revealed that there were significant differences in the percentage of S + G2M phase, a value of MTT and the expression rate of PCNA protein in three groups (P <0.01). Sense CyclinD1 eukaryotic expression vectors could have a positive effect on the proliferation of ASMC, however the antisence one have a negative effect, which implicated that CyclinD1 might contribute to the process of airway smooth muscle cell proliferation.


Subject(s)
Asthma/pathology , Cell Proliferation/drug effects , Cyclin D1/antagonists & inhibitors , DNA, Antisense/pharmacology , Myocytes, Smooth Muscle/drug effects , Animals , Cell Cycle/drug effects , Codon/genetics , Codon/pharmacology , Cyclin D1/agonists , Cyclin D1/genetics , DNA, Antisense/genetics , Disease Models, Animal , Gene Expression , Genetic Vectors/genetics , Male , Myocytes, Smooth Muscle/pathology , Rats , Rats, Sprague-Dawley , Recombination, Genetic/genetics , Respiratory System , Reverse Transcriptase Polymerase Chain Reaction , Transduction, Genetic , Transfection
10.
Chin J Integr Med ; 14(1): 51-5, 2008 Mar.
Article in English | MEDLINE | ID: mdl-18568329

ABSTRACT

OBJECTIVE: To investigate the role of Shenfu Injection (SFI) in rats with systemic inflammatory response syndrome (SIRS). METHODS: The SIRS rat model was induced by the intravenous injection of lipopolysaccharide (LPS). Forty-five male Wistar rats were randomly divided into 3 groups, the sham operative control group (control group, n=5), the SIRS model group (model group, n=20) and the SFI treatment group (SFI group, n=20). LPS was injected through the external jugular vein (12 mg/kg, 6 mg/mL) to all rats except for those in the control group, and SFI (10 mL/kg) was given to those in the SF group only once through intraperitoneal injection, while the normal saline (10 mL/kg) was given to those in the model group. For those in the control group, normal saline was given through the external jugular vein (2 mL/kg) and intraperitoneal injection (10 mL/kg). Then, rats in the model group and SFI group were divided into 4 subgroups according to the time points, i.e., 1 h, 2 h, 4 h and 6 h subgroups, 5 rats in each group. The activity of nuclear factor of kappa B (NF-kappa B) of in blood mononuclear cells and the plasma levels of tumor necrosis factor-alpha (TNF-alpha) and interleukin 6-(IL-6) were determined using enzyme-linked immunoabsordent assay (ELISA) at 1 h, 2 h, 4 h and 6 h after modeling. Histopathologic changes of the lung and liver were observed under a light microscope. RESULTS: Compared with the control group, the activity of NF-kappa B in mononuclear cells and the plasma level of TNF-alpha were obviously increased at each time points (all P<0.01), reaching the peaks at 2 h after modeling. The plasma level of IL-6 increased gradually as time went by in the model group (P<0.01). Pathological examination showed pulmonary alveoli hemorrhage, edema and inflammatory cell infiltration in the lung tissue, and angiotelectasis, congestion, and local necrosis in the liver tissue in the model group. Compared with the model group, the activity of NF-kappa B and the levels of TNF-alpha and IL-6 in plasma decreased significantly in the SFI group (P<0.01), and the pathological injury in the lungs and liver was significantly alleviated. CONCLUSION: SFI plays a protective role by inhibiting the activity of NF-kappaB, and reducing the expressions of TNF-alpha and IL-6 in SIRS rats.


Subject(s)
Aconitum , Panax , Plant Extracts/therapeutic use , Systemic Inflammatory Response Syndrome/drug therapy , Animals , Injections , Interleukin-6/blood , Liver/pathology , Lung/pathology , Male , NF-kappa B/metabolism , Rats , Rats, Wistar , Systemic Inflammatory Response Syndrome/blood , Systemic Inflammatory Response Syndrome/pathology , Tumor Necrosis Factor-alpha/blood
11.
J Huazhong Univ Sci Technolog Med Sci ; 28(3): 251-6, 2008 Jun.
Article in English | MEDLINE | ID: mdl-18563317

ABSTRACT

Whether inhibiting the activity of nuclear factor (NF)-kappaB potentiates cisplatin-induced apoptosis in non-small cell lung cell line A549 cells was investigated. The recombinant plasmid pcDNA3.1 (+)/IkappaBalpha expressing IkappaBalpha was constructed. The in vitro cultured A549 cells were transfected with pcDNA3.1 (+)/IkappaBalpha alone, or pcDNA3.1 (+)/IkappaBalpha combined with cisplatin. The mitochondrial membrane potential (Deltapsim) was determined by rhodamine 123, the activity of caspase-3 was tested by colorimetric assay, and cell apoptosis was detected by flow cytometry with the annexin V /propidium iodide assay. The results showed that the activity of NF-kappaB in A549 cells was inhibited by transfecting pcDNA3.1(+)/IkappaBalpha. Transfection of pcDNA3.1(+)/IkappaBalpha alone did not promote apoptosis. Treatment of cisplatin alone had a little effect on cell apoptosis. Transfection of pcDNA3.1(+)/IkappaBalpha combined with cisplatin treatment significantly induced apoptosis of A549 cells. It was concluded that inhibiting the activity of NF-B potentiated cisplatin-induced apoptosis of A549 cells.


Subject(s)
Antineoplastic Agents/pharmacology , Apoptosis , Cisplatin/pharmacology , NF-kappa B/antagonists & inhibitors , NF-kappa B/metabolism , Caspase 3/metabolism , Cell Line, Tumor , Cell Nucleus/metabolism , Fluorescent Dyes/pharmacology , Humans , I-kappa B Proteins/metabolism , Membrane Potentials , Mitochondria/metabolism , NF-KappaB Inhibitor alpha , Plasmids/metabolism , Rhodamine 123/pharmacology , Transfection
12.
Acta Pharmacol Sin ; 29(6): 677-86, 2008 Jun.
Article in English | MEDLINE | ID: mdl-18501114

ABSTRACT

AIM: To determine whether protein kinase C (PKC) has any effect on the expression of cyclinD1, a key regulator of growth control and G1/S transition, and to investigate the underlying molecular mechanisms of PKC involving the remodeling of the asthmatic airway smooth muscle (ASM). METHODS: The treatment of synchronized ASM cells from asthmatic rats with PKC-specific agonist phorbol 12-myristate 13-acetate (PMA) and antagonist 2-{1-[3-(amidinothio) propyl]-1Hindol-3-yl}-3-(1-methylindol-3-yl) maleimide methanesulfonate salt (Ro31-8220) was followed by the proliferation assay. PKCalpha and cyclinD1 expressions in ASM cells (ASMC) were detected by RT-PCR and Western blotting. The relation between PKCalpha and cyclinD1 was assessed by linear regression analysis. The effect of the construct recombinant plasmid pcDNA3.1-antisense cyclinD1 (pcDNA3.1-ascyclinD1) on the proliferation of ASMC was found to be induced by PMA. RESULTS: The data showed phorbol ester-dependent PKCalpha promoted the proliferation of ASMC. The closely-positive correlation existed between the expression of PKCalpha and cyclinD1 at the transcriptional (r=0.821, P<0.01) and translational (r=0.940, P<0.01) levels. pcDNA3.1-ascyclinD1 could inhibit the proliferation of ASMC. pcDNA3.1-ascyclinD1 almost completely attenuated the PMA-induced proliferation effect as Ro31-8220+pcDNA3.1. CONCLUSION: The proliferation of ASMC by PKC might by regulated by the cyclinD1 expression in asthmatic rats.


Subject(s)
Asthma/pathology , Cell Proliferation/drug effects , Cyclin D1/biosynthesis , Myocytes, Smooth Muscle/drug effects , Myocytes, Smooth Muscle/pathology , Protein Kinase C/physiology , Animals , Cells, Cultured , Cyclin D1/genetics , DNA Fingerprinting , Gene Expression Regulation , Male , Plasmids/genetics , Proliferating Cell Nuclear Antigen/metabolism , Rats , Rats, Inbred BN
13.
Exp Mol Med ; 40(6): 686-98, 2008 Dec 31.
Article in English | MEDLINE | ID: mdl-19116454

ABSTRACT

Intestinal ischemia-reperfusion (I/R) is an important event in the pathogenesis of multiple organ dysfunction syndrome (MODS). The aim of this study is to determine the effects of ginsenoside Rb1 on liver injury induced by intestinal I/R in rats. Adult male Wistar rats were randomly divided into four groups: (1) a control, sham-operated group (sham group); (2) an intestinal I/R group subjected to 1 h intestinal ischemia and 2 h reperfusion (I/R group); (3) a group treated with 20 mg/kg ginsenoside Rb1 before reperfusion (Rb1-20 group); and (4) a group treated with 40 mg/kg ginsenoside Rb1 before reperfusion (Rb1-40 group). Liver and intestinal histology was observed. Aspartate aminotransferase (AST), alanine aminotransferase (ALT) level in serum and malondialdehyde (MDA) level in intestinal tissues were measured. Myeloperoxidase (MPO), TNF-alpha, MDA level and immunohistochemical expression of NF-kgr;B and intracellular adhesion molecule-1 (ICAM-1) in liver tissues was assayed. In addition, a western blot analysis of liver NF-kappaB expression was performed. Results indicated intestinal I/R induced intestinal and liver injury, which was characterized by increase of AST and ALT in serum, MDA level in intestine, MPO, TNF-alpha and MDA level and ICAM-1 and NF-kappaB expression in the liver tissues. Ginsenoside Rb1 (20, 40 mg/kg) ameliorated liver injury, decreased MPO, TNF-alpha and MDA level, NF-kappaB and ICAM-1 expression in liver tissues. In conclusion, ginsenoside Rb1 ablated liver injury induced by intestinal I/R by inhibiting NF-kappaB activation.


Subject(s)
Ginsenosides/pharmacology , Intestines/blood supply , Liver Diseases/pathology , NF-kappa B/antagonists & inhibitors , Reperfusion Injury/pathology , Alanine Transaminase/blood , Animals , Aspartate Aminotransferases/blood , Biomarkers/metabolism , Intercellular Adhesion Molecule-1/metabolism , Intestinal Mucosa/metabolism , Intestines/pathology , Ischemia/metabolism , Ischemia/pathology , Liver/enzymology , Liver/pathology , Liver Diseases/etiology , Male , Malondialdehyde/metabolism , NF-kappa B/metabolism , Peroxidase/metabolism , Rats , Rats, Wistar , Reperfusion Injury/complications , Tumor Necrosis Factor-alpha/metabolism
14.
Zhonghua Jie He He Hu Xi Za Zhi ; 31(12): 915-20, 2008 Dec.
Article in Chinese | MEDLINE | ID: mdl-19134409

ABSTRACT

OBJECTIVE: To explore the role of PKCalpha-ERK1/2 cascade in PMA induced up-regulation of cyclinD1 and P21(cip1) in human airway smooth muscle cells (HASMCs) sensitized by sera from atopic asthmatics. METHODS: HASMCs in cultures were passively sensitized by 10% serum from asthmatic patients and were randomly divided into five groups: the control group, PMA treated group, PMA and PKCalpha mismatched Oligodeoxynucleotides (PKCalpha-mmODN) treated group, PMA and PKCalpha antisense Oligodeoxynucleotides (PKCalpha-asODN) treated group, PMA and U0126 (MAP Kinase Kinase inhibitor)treated group. The expression of p-PKCalpha, ERK1/2, p-ERK1/2, cyclinD1 and P21(cip1) protein were determined by western blotting. The proliferation of HASMC was examined by cell cycle analysis and MTT colorimetric assay. RESULTS: Compared with the control group, the expression of p-PKCalpha and ERK1/2, p-ERK1/2 protein increased, the expression of cyclinD1, P21(cip1) protein increased correspondingly (the A value % control was 2.10 +/- 0.29, 1.67 +/- 0.19, 2.20 +/- 0.27, 1.99 +/- 0.22 and 3.11 +/- 0.29 respectively; q value was 9.87, 7.06, 10.57, 11.10 and 20.33 respectively; all P < 0.05) in PMA treated group, and cells proliferation [the percentage of cells in S phase was (30.3 +/- 2.4)%, A(490) value was 0.80 +/- 0.06] enhanced significantly compared with those [the percentage of cells in S phase was (13.9 +/- 2.6)%, A(490) value was 0.41 +/- 0.04] of the control group (q = 6.07, 12.63; all P < 0.05). In PMA and PKCalpha-asODN treated group, the level of p-PKCalpha decreased, the expression of ERK1/2, p-ERK1/2 and the expression of cyclinD1, P21(cip1) decreased correspondingly (the A value % control was 1.23 +/- 0.19, 1.34 +/- 0.18, 1.52 +/- 0.20, 1.45 +/- 0.18 and 1.49 +/- 0.18 respectively; q value was 7.49, 3.58, 5.97, 6.06 and 15.65 respectively; all P < 0.05), and cells proliferation reduced significantly [the percentage of cells in S phase was (21.2 +/- 2.8)%, A(490) value was 0.51 +/- 0.04; q = 6.07, 12.63; all P < 0.05], as compared with those of the PMA treated group. In PMA and U0126 treated group, the level of p-PKCalpha had no significant change (A value was1.99 +/- 0.18, q = 0.94, P > 0.05), but the levels of ERK1/2, p-ERK1/2 decreased, the expression of cyclinD1, P21(cip1) reduced (the A value % control was 0.95 +/- 0.21, 1.15 +/- 0.19, 1.37 +/- 0.15 and 1.96 +/- 0.21 respectively; q value was 7.79, 9.16, 6.92 and 11.16 respectively; all P < 0.05), and cells proliferation reduced significantly [the percentage of cells in S phase was (22.0 +/- 3.2)%, A(490) value was 0.49 +/- 0.03; q = 5.51, 13.45; all P < 0.05], as compared with those of the PMA treated group. CONCLUSION: ERK1/2 is one of the downstream regulators of PKCalpha, and PKCalpha-ERK1/2 cascade is involved in PMA induced up-regulation of cyclinD1 and P21(cip1) and proliferation in HASMC sensitized by sera from atopic asthmatics.


Subject(s)
Asthma/metabolism , Cyclin D1/metabolism , Cyclin-Dependent Kinase Inhibitor p21/metabolism , Extracellular Signal-Regulated MAP Kinases/metabolism , Myocytes, Smooth Muscle/metabolism , Protein Kinase C-alpha/metabolism , Adult , Asthma/blood , Cell Cycle , Cell Proliferation , Cells, Cultured , Female , Gene Expression Regulation , Humans , Male , Middle Aged , Mitogen-Activated Protein Kinase 3/metabolism , Myocytes, Smooth Muscle/cytology , Signal Transduction , Up-Regulation , Young Adult
15.
Article in Chinese | WPRIM (Western Pacific) | ID: wpr-284595

ABSTRACT

Whether inhibiting the activity of nuclear factor (NF)-κB potentiates cisplatin-induced apoptosis in non-small cell lung cell line A549 cells was investigated. The recombinant plasmid pcDNA3.1(+)/IκBα expressing IκBα was constructed. The in vitro cultured A549 cells were trans-fected with pcDNA3.1(+)/IκBα alone, or pcDNA3.1(+)/IκBα combined with cisplatin. The mitochondrial membrane potential (△ψm) was determined by rhodamine 123, the activity of caspase-3 was tested by colorimetric assay, and cell apoptosis was detected by flow cytometry with the annexin V/propidium iodide assay. The results showed that the activity of NF-κB in A549 cells was inhibited by transfecting pcDNA3.1(+)/IκBα. Transfection of pcDNA3.1(+)/IκBα alone did not promote apoptosis. Treatment of cisplatin alone had a little effect on cell apoptosis. Transfection of pcDNA3.1(+)/IκBα combined with cisplatin treatment significantly induced apoptosis of A549 cells. It was concluded that inhibiting the activity of NF-κB potentiated cisplatin-induced apoptosis of A549 cells.

16.
Zhonghua Jie He He Hu Xi Za Zhi ; 30(10): 771-5, 2007 Oct.
Article in Chinese | MEDLINE | ID: mdl-18218209

ABSTRACT

OBJECTIVE: To investigate the nuclear factor (NF)-kappaB activity in human non-small cell lung cancer (NSCLC) tissues and to explore the correlation between NF-kappaB activity and cell proliferation, between NF-kappaB activity and cell spontaneous apoptosis. METHODS: Thirty samples of non-small cell lung cancer tissues and 15 normal lung tissues were collected from May to October in 2006. NF-kappaB activation was determined by electrophoretic mobility shift assay (EMSA). CyclinD1 level was examined by RT-PCR and Western blot. Proliferation cell nuclear antigen (PCNA) protein was examined by immunohistochemical analysis. Spontaneous cell apoptosis was determined by the TUNEL method. RESULTS: There was significant difference (F=78.96, P<0.01) in NF-kappaB activity among normal lung tissue group (24,826+/-3724), squamous-cell carcinoma tissue group (28,028+/-4204), and adenocarcinoma tissue group (35,425+/-5317). The NF-kappaB activity in the squamous-cell carcinoma group and the adenocarcinom tissue group was higher than that in the normal lung tissue group (all P<0.01); and the NF-kappaB activity is in the adenocarcinoma tissue group was higher compared with that in the squamous-cell carcinoma group (P<0.05). There was significant difference (F=62.43, P<0.01) in the cyclinD1 mRNA level among normal lung tissue group (2.04+/-0.24), the squamous-cell carcinoma group (2.91+/-0.37), and the adenocarcinoma group (4.13+/-0.36). There was significant difference (F=89.24, P<0.01) in cyclinD1 protein level among normal lung tissue group (0.31+/-0.06), the squamous-cell carcinoma group (0.43+/-0.07), and the adenocarcinoma group (0.58+/-0.08). There was significant difference (F=45.61, P<0.01) in PCNA protein level among the normal lung tissue group (0.32+/-0.09), the squamous-cell carcinoma group (0.42+/-0.10), and the adenocarcinima group (0.54+/-0.16). There was no significant difference (F=1.86, P>0.05) in apoptosis index among the normal lung tissue group (2.58%+/-0.39%), the squamous-cell carcinoma group (2.27%+/-0.34%), and the adenocarcinoma group (2.92%+/-0.59%). The NF-kappaB activity was positively correlated with cyclin D1 mRNA level, cyclin D1 protein level, and PCNA protein level in the squamous-cell carcinoma group (r=0.51, P<0.05, r=0.54, P<0.05, r=0.60, P<0.05), respectively; the NF-kappaB activity was also positively correlated with cyclinD1mRNA, cyclinD1protein level, and PCNA protein level in the adenocarcinoma group (r=0.60, P<0.05; r=0.64, P<0.05; r=0.68, P<0.05), respectively. The NF-kappaB activity in the squamous-cell group and the adenocarcinoma group was not related to cell apoptosis index. CONCLUSION: NF-kappaB activity increased in NSCLC tissues. Abnormal NF-kappaB activation may be associated with cell proliferation, but do not affect spontaneous cell apoptosis in NSCLC tissues.


Subject(s)
Carcinoma, Non-Small-Cell Lung/pathology , Cell Proliferation , Lung Neoplasms/pathology , NF-kappa B/metabolism , Adult , Aged , Aged, 80 and over , Apoptosis , Blotting, Western , Carcinoma, Non-Small-Cell Lung/genetics , Carcinoma, Non-Small-Cell Lung/metabolism , Carcinoma, Squamous Cell/genetics , Carcinoma, Squamous Cell/metabolism , Carcinoma, Squamous Cell/pathology , Cyclin D1/genetics , Cyclin D1/metabolism , Electrophoretic Mobility Shift Assay , Female , Humans , Lung/metabolism , Lung/pathology , Lung Neoplasms/genetics , Lung Neoplasms/metabolism , Male , Middle Aged , Proliferating Cell Nuclear Antigen/metabolism , RNA, Messenger/genetics , RNA, Messenger/metabolism , Reverse Transcriptase Polymerase Chain Reaction
SELECTION OF CITATIONS
SEARCH DETAIL
...